{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:41:51Z","timestamp":1790008911647,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clinthera.2013.10.009","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T03:15:43Z","timestamp":1385608543000},"page":"1946-1954","source":"Crossref","is-referenced-by-count":84,"title":["Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Marije","family":"Slingerland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max E.","family":"Scheulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J.C.","family":"van Warmerdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2013.10.009_bib1","first-page":"S3","article-title":"Taxol (paclitaxel): mechanisms of action","volume":"5","author":"Horwitz","year":"1994","journal-title":"Ann Oncol"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2013.10.009_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology","volume":"23","author":"Joerger","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2013.10.009_bib3","first-page":"605","article-title":"Phase I trial of Taxol given as a 3-hour infusion every 21 days","volume":"70","author":"Kris","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clinthera.2013.10.009_bib4","first-page":"1171","article-title":"Phase I trial of Taxol in patients with advanced cancer","volume":"71","author":"Donehower","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clinthera.2013.10.009_bib5","first-page":"585a","article-title":"Incidence, course, and severity of taxoid-induced hypersensitivity reactions in 646 oncology patients","volume":"18","author":"Tyson","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clinthera.2013.10.009_bib6","first-page":"1454","article-title":"Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications","volume":"59","author":"Sparreboom","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib7","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2013.10.009_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jps.2600830710","article-title":"Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine","volume":"83","author":"Burke","year":"1994","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2013.10.009_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001813-199502000-00010","article-title":"Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts","volume":"6","author":"Daoud","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2013.10.009_bib10","first-page":"461","article-title":"Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan","volume":"7","author":"Subramanian","year":"1995","journal-title":"Oncol Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0304-3835(98)00031-7","article-title":"Effect of liposomalization on the anti-tumor activity, side effects and tissue distribution of CPT-11","volume":"127","author":"Sadzuka","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clinthera.2013.10.009_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002800050965","article-title":"Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice","volume":"44","author":"Knight","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2013.10.009_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1389200003339225","article-title":"Effective prodrug liposome and conversion to active metabolite","volume":"1","author":"Sadzuka","year":"2000","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2013.10.009_bib14","first-page":"3389","article-title":"Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models","volume":"60","author":"Tardi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drudis.2011.09.015","article-title":"Liposomal drug formulations in cancer therapy: 15 years along the road","volume":"17","author":"Slingerland","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2013.10.009_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/01.coc.0000054888.02055.4E","article-title":"Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer","volume":"27","author":"Flaherty","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2013.10.009_bib17","first-page":"23","article-title":"Phase I study of liposome encapsulated mitoxantrone (LEM) in patients with advanced cancers","volume":"13","author":"Fishman","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.10.009_bib18","first-page":"86","article-title":"Phase I trials of liposome encapsulated mitoxantrone (LEM) and SN-38 (LE-SN38)","volume":"22","author":"Fishman","year":"2004","journal-title":"Cancer Invest"},{"issue":"12","key":"10.1016\/j.clinthera.2013.10.009_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1078-0432.CCR-05-1260","article-title":"Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies","volume":"15","author":"Dritschilo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib20","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1158\/1078-0432.CCR-04-0642","article-title":"Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study","volume":"10","author":"Rudin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2013.10.009_bib21","first-page":"4492s","article-title":"Phase I trial in advanced malignancies with liposome encapsulated paclitaxel (LEP)","volume":"6","author":"Treat","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejpb.2004.06.009","article-title":"Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation","volume":"59","author":"Zhang","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2013.10.009_bib23","first-page":"1035","article-title":"Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel","volume":"12","author":"Cabanes","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clinthera.2013.10.009_bib24","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-08-1046","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel","volume":"14","author":"Fetterly","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib25","unstructured":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: statistical approaches to establishing bioequivalence. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070244.pdf. Accessed [date]. August 2013."},{"key":"10.1016\/j.clinthera.2013.10.009_bib26","first-page":"5877","article-title":"Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model","volume":"53","author":"Sharma","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2013.10.009_bib27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jps.2600841204","article-title":"Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice","volume":"84","author":"Sharma","year":"1995","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2013.10.009_bib28","first-page":"69","article-title":"Novel Taxol formulations: Taxol-containing liposomes","volume":"15","author":"Straubinger","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.clinthera.2013.10.009_bib29","unstructured":"US National Institutes of Health. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. http:\/\/clinicaltrials.gov. Accessed August 1, 2013."},{"key":"10.1016\/j.clinthera.2013.10.009_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1634\/theoncologist.2007-0180","article-title":"Concept and clinical evaluation of carrier-mediated anticancer agents","volume":"13","author":"Zamboni","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2013.10.009_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/13543784.17.3.335","article-title":"New taxanes in development","volume":"17","author":"Ferlini","year":"2008","journal-title":"Exp Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2013.10.009_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2013.02.058","article-title":"Taxanes: old drugs, new oral formulations","volume":"717","author":"Jibodh","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.10.009_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/annonc\/mdr300","article-title":"Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis","volume":"23","author":"Fasol","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813010308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813010308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T17:22:36Z","timestamp":1539019356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813010308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0149291813010308"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}